Avalo Therapeutics Inc (AVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $448.71M
Last updated: Nov 17, 2026 at 4:10 PM ET
Avalo Therapeutics Inc (AVTX) Stock Chart
Avalo Therapeutics (AVTX) has a latest price of $7.13 on Nov 17, 2026, 70.6% below its 52-week high of $24.27. Its price fell 52.8% over the past 12 months. The month-end price fell 99.9% over the 10 years through Oct 2026, a compound annual decline of 51.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $20,465.33 in Feb 2019 and its lowest $4.00 in May 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart AVTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for AVTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 65.6%, and over 6 months it fell 56.2%. The month-end price fell 72.5% over the 3 years through Oct 2026, a compound annual decline of 35.0%.
| Period | Change |
|---|---|
| 1 month | -38.5% |
| 3 months | -65.6% |
| 6 months | -56.2% |
| 12 months | -52.8% |
| 12 months, with dividends | -52.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -72.5% | -35.0% |
| 5 years | -99.9% | -74.5% |
| 10 years | -99.9% | -51.8% |
Price by Year
Its best calendar year was 2017, when the price rose 263.5%, and its weakest was 2023, when it fell 99.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $7.17 | -60.5% |
| 2025 | $18.16 | +144.4% |
| 2024 | $7.43 | -18.4% |
| 2023 | $9.10 | -99.2% |
| 2022 | $1,200.02 | -75.3% |
| 2021 | $4,859.09 | -35.6% |
| 2020 | $7,545.88 | -51.0% |
| 2019 | $15,406.16 | +66.9% |
| 2018 | $9,232.26 | +0.9% |
| 2017 | $9,146.52 | +263.5% |
Trading Range
The price is 39.8% below its 50-day average of $11.84 and 54.1% below its 200-day average of $15.54.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $7.13 | |
| 52-week high | $24.27 | -70.6% |
| 52-week low | $6.53 | +9.2% |
| 50-day average | $11.84 | -39.8% |
| 200-day average | $15.54 | -54.1% |
Price Risk
Over 3 years, its largest fall from a peak was 83.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.57 |
| Largest fall, 1 year | -71.0% |
| Largest fall, 3 years | -83.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About AVTX
What is AVTX's 1-year price change?
Avalo Therapeutics's price fell 52.8% over the past 12 months. With dividends included, the 12-month total return was -52.8%.
What is AVTX's 5-year price change?
Avalo Therapeutics's month-end price fell 99.9% over the 5 years through Oct 2026, a compound annual decline of 74.5%. These figures leave out dividends.
What is AVTX's 52-week high and low?
Avalo Therapeutics's 52-week high is $24.27 and its 52-week low is $6.53. Its latest price of $7.13 on Nov 17, 2026 is 70.6% below the high.
What is AVTX's beta?
Avalo Therapeutics's 1-year beta against the S&P 500 is 1.57, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 71.0%.
Is the AVTX chart free?
Yes. Advanced Charting for AVTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
AVTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors